Physician profile
May Hashimi
NPI 1154342293
$3,365.03
in general payments reported to CMS, 2019-2025
22 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,528 · 2020: $745 · 2021: $448 · 2022: $267 · 2023: $19.19 · 2024: $193 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $276 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $276.11 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $573.86 | 2019-2022 | |
| Genentech USA, INC. | $450.71 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $346.75 | 2019-2022 | |
| Janssen Biotech, INC. | $253.56 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $239.42 | 2019-2021 | |
| Pfizer INC. | $239.15 | 2019-2022 | |
| Dova Pharmaceuticals | $202.04 | 2019-2020 | |
| Emd Serono, INC. | $142.57 | 2019-2021 | |
| Sobi, INC | $115.33 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $111.75 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $97.48 | 2019-2024 | Calquence |
| Abbvie INC. | $94.49 | 2021-2022 | |
| Gilead Sciences, INC. | $92.81 | 2019-2024 | |
| Tempus Ai, INC | $87.13 | 2024 | |
| Springworks Therapeutics, INC. | $63.55 | 2025 | Ogsiveo, Gomekli |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $59.30 | 2019 | |
| Genzyme Corporation | $57.87 | 2019-2023 | |
| Celgene Corporation | $53.76 | 2020-2021 | |
| Seagen INC. | $33.71 | 2019 | |
| Astellas Pharma US INC | $21.88 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.10 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw May Hashimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.